The Intestinal Immunomodulation research group of the Biosanitary Research Institute of Granada (ibs.GRANADA) has shown that the administration of mesenchymal stromal cells from human intestinal tissue protects against the development of colorectal cancer associated with colitis (CAC), and may be a treatment promising for inflammatory bowel disease.
Inflammatory bowel disease (IBD) is a condition that affects millions of people worldwide and is associated with an increased risk of developing colorectal cancer. While the origins of IBD remain a mystery, it is believed to involve environmental factors, genetic predisposition, imbalance in the gut microbiota (dysbiosis), and defects in the immune system. This study has shed light on a possible promising therapy for this disease.
In this study, the team of scientists from Granada evaluated the impact of injections of mesenchymal stromal cells in the treatment of IBD and its effect on the development of tumors in the colon in an animal model. These mesenchymal stromal cells came from human intestinal tissue that expanded vitro.
The results revealed a significant inhibition of the development of intestinal inflammation and tumors, which was associated with a modulation of the altered immune response. The treatment reduced the migration of monocytes to the colon, and their subsequent differentiation into macrophages, while increasing the number of regulatory T cells. Likewise, the intestinal dysbiosis that characterizes this disease improved, increasing microbial diversity and the proportion of Bacillota/Bacteridota, as well as the abundance of Akkermania, while reducing the levels of the genres Alistipes y Turicibacter, associated with the intestinal inflammatory process.
In summary, this study demonstrates that the administration of these intestinal mesenchymal stromal cells protects against the development of CAC in mice, improving the intestinal inflammatory process and partially reversing intestinal dysbiosis. These results support the idea of using mesenchymal stromal cells as a promising therapy for the treatment of IBD. This finding could open new perspectives in the search for more effective treatments for people who suffer from IBD and have a higher risk of developing CAC.
This study represents an important step in the understanding and treatment of IBD and CAC. Researchers are already conducting new research to expand on these findings and improve the quality of life for those suffering from these conditions.
About the group
The MP16-Intestinal Immunomodulation research group at ibs.GRANADA is responsible for developing strategies for the diagnosis, prevention and treatment of digestive and metabolic diseases, aimed at modulating the intestinal immune system and the microbiota with different therapeutic strategies. The researchers who are members of the group who carried out the study are staff from the Department of Pharmacology of the University of Granada, and from the General Surgery Services of the Virgen de las Nieves University Hospital and the San Cecilio Clinical University Hospital (Granada).
More information about the group: https://www.ibsgranada.es/grupos-de-investigacion/mp16-inmunomodulacion-intestinal/
Bibliographic reference:
Hidalgo-García et al. Administration of intestinal mesenchymal stromal cells reduces colitis-associated cancer in C57BL/6J mice modulating the immune response and gut dysbiosis. Pharmacol Res. 2023 Sep;195:106891. doi: 10.1016/j.phrs.2023.106891.
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
Researchers have confirmed that patients with NK lymphocytes present i...
